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Transgenic expression of Bach1 transcription factor results in megakaryocytic impairment
Introduction
The Maf recognition element (MARE) is known to act as a critical cis-regulatory element for erythroid and megakaryocytic genes, including various globin and heme biosynthetic enzyme genes. [1] [2] [3] [4] [5] A MARE-specific binding activity was first identified as NF-E2, a heterodimeric protein complex whose subunits consist of p45 and p18. [6] [7] p18 is one of the small Maf transcription factors (MafK, MafG and MafF), 7 while the p45 subunit is most closely related to the Drosophila nuclear regulatory protein Cap'n collar (CNC). 6, 8 Both CNC and small Maf proteins possess a basic region-leucine zipper (bZip) structure, which mediates the DNA binding and dimerization activities. The MARE can be bound by various sets of transcription factor heterodimers consisting of Maf and CNC family members, including p45, Nrf1, Nrf2, Nrf3, Bach1 and Bach2. [9] [10] [11] [12] [13] Among the CNC family members, Bach1 and Bach2 function as transcription repressors, whereas the others are transcription activators. 12, 13, [14] [15] [16] MAREs play critical roles in the enhancer function of the -globin locus control region (LCR). 1 Biochemical and ChIP studies have shown that the Bach1/small Maf heterodimer binds to MAREs within the G globin LCR in murine erythroid leukemia (MEL) cells prior to terminal differentiation. [17] [18] [19] 
Following dimethylsulfoxide (DMSO)-induced terminal differentiation of MEL cells, NF-E2 binds to
MAREs to activate transcription. 18, 19 These results suggest that the exchange of p45 for Bach1as a MafK dimerization partner is a key step in the switch from the repressed to the active state in erythroid lineage cells. This shift is associated with changes in the interaction of MafK with co-repressors and co-activators. 18 However, studies of CNC, Bach, and small Maf mutant mice have not been able to demonstrate the importance of these factors in globin gene expression. Thus, further studies are necessary.
The functions of CNC and small Maf proteins in megakaryocytes have been well only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From documented by studies of mouse genetics. p45 is expressed in megakaryocytic as well as in erythroid cells. 6, 20 Homozygous disruption of the mouse p45 gene results in defective megakaryopoiesis and profound thrombocytopenia, leading to postnatal death, whereas erythroid abnormalities are only mild in these mice. 21 When cultured in vivo, p45 -/-megakaryocytes never develop proplatelets, 22 which are considered to be the immediate precursors of blood platelets. 23 Recent studies have shown that p45 is essential for the expression of a subset of specific genes in the late stages of megakaryopoiesis. To date, several genes that act downstream of p45 in megakaryocytes have been identified. [24] [25] [26] [27] ChIP studies have demonstrated recruitment of p45 to the MAREs within the promoters of the p45 targets in a cell line with a megakaryocytic lineage. 28 Small maf mutant mice, as well as mafG and mafG::mafK compound mice also showed mild and severe thrombocytopenia, respectively, demonstrating that p45 and small Maf proteins function cooperatively in vivo. 29, 30 On the other hand, we previously reported that Bach1 is expressed in megakaryocytes as well as in erythrocytes. 31 However, no abnormality of platelet counts was observed in bach1-null mutant mice (Igarashi K, unpublished results). Therefore, the functions of Bach1 and the functional relationships between Bach1 and p45 in these cells remain unclear.
To investigate these relationships, we established transgenic mouse lines bearing the human BACH1 cDNA under control of the GATA-1 gene hematopoietic regulatory domain (G1-HRD), that restricts transgene expression to erythroid and megakaryocytic cells. 32 Using this model system, we can evaluate the specific functions of the gene in the two lineages of cells. We show here that overexpression of BACH1 in vivo resulted in a significant reduction in the number of platelets in peripheral blood, due to a maturation arrest of megakaryocytes.
Thus, BACH1 transgenic mice phenocopy p45-null mutant mice. This suggests that MARE-dependent genes are positively regulated by p45 and negatively regulated by Bach1 in megakaryocytes.
only.
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Materials and methods
Generation of transgenic mouse
A cDNA fragment containing human BACH1 was cloned into an expression cassette downstream of the IE3.9int GATA-1 promoter. The construct was injected into fertilized BDF-1 eggs using standard procedures as described before. 32 The BACH1 transgenic mice were identified by polymerase chain reaction (PCR) methods using primer pairs 
ChIP assay
Chromatin fixation and purification procedures were as described previously. 17 In brief, 3ዊ 10 7 UT-7/EPO or UT-7/TPO cells were fixed by adding formaldehyde to 1% final concentration for 7 min at room temperature. Cells were then sonicated to prepare chromatin suspensions containing DNA that was 500 to 1,000 bp in length. Immunoprecipitations were carried out as described previously. 19 For the ChIP assay, an anti-Bach (A1-5) antibody was used 17 . Normal mouse IgG (Santa Cruz Biotechnology Inc., Santa Cruz, CA) was used for negative control experiments. PCR reactions were carried out by using Ex Taq DNA only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From polymerase (Takara Bio Inc., Otsu). PCR products were electrophoresed using a Bioanalyzer 2100 and the DNA 1000 LabChip kit (Agilent Technologies, Palo Alto, CA). Primers (5' to 3') were as follows: nfe2-1, ATTTTCCACCCCTCCGTCAACC and GTGATCTCA GCTCGTTGCAACCTC; nfe2-3 s, CAGAGTACAAGTCCGTGGTTAC and CAGGCAACC AAGCAAACATCAC; Exon 13, ATTCAA AGAAAACCCTAAGTGTGG and AGAACCTCTTATCCTTGCATGC.
Construction of plasmid vectors
A 535 bp fragment corresponding to the 5'-flanking region of the TXAS promoter was amplified by PCR using the following set of primers (sense: 5'-CTACTCGAGTTGGTGGGATGGTTGTCC-3' and antisense: 5'-GGTAAGCTTCCAGGTGAGACAGGAGGC-3') and 0.1 µg of genomic DNA extracted from the human myeloid leukemia cell line HEL. 24 The PCR products were then subcloned into the Picagene basic vector (Toyo ink, Tokyo, Japan). The human BACH1 expression vector was prepared by sucbloning the human BACH1 full-length cDNA clone #63 35 into the mammalian expression vector pcDNA3.1 (Invitrogen Life Technologies, Carlsbad, CA). The Bach1-MafK fusion expression plasmids (B1K) was described before.
36
Reporter gene assays
For transient transfection assays, quail fibroblast QT6 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and seeded in 12-well dishes 24 hours before transfection. 
Hematological analysis
Caudal artery blood was collected from anesthetized mice, and the peripheral blood white blood cell count, hematocrit, concentration of hemoglobin, and platelet count were determined using an automatic blood cell analyzer, MEK-6358 (Nihon Koden, Tokyo).
Histological analysis
Samples of the femur, spleen, and liver were removed from wild-type littermates and transgenic mice after they were killed. Samples were fixed in 10% buffered formaldehyde solution, embedded in paraffin, and stained with hematoxylin and eosin (HE) and silver impregnation. 
Ultrastructural analysis
Bone marrow samples were freshly obtained from transgenic mice and their wild-type littermates, and were fixed in 2.5% glutaraldehyde and buffered in 0.1M sodium cacodylate for two hours. Following post-fixation with 0.1% osmium tetroxide for one hour, the specimens were dehydrated using an ascending series of ethanol solutions and embedded in Epon 812. Ultrathin sections stained with uranyl acetate and lead citrate were observed using a JOEL TEM-2000EX electron microscope.
Western blot analysis
Whole tissue extract was prepared from spleens and livers of transgenic mice and their wild-type littermates according to methods described previously 17 . Western blot analysis was performed according to standard protocols. 35 Tissue extracts were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to Hybond-P membranes (Amersham Bioscience KK, Tokyo), and incubated with a 1:2000 dilution of anti-Bach1 rabbit antisera (A1-5) 17 for one hour at room temperature. Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG (Amersham Bioscience KK, Tokyo) was used as a second antibody.
HRP activity was detected using the ECL system (Amersham Bioscience KK, Tokyo).
Northern blot analysis
Total cellular RNA was isolated by the guanidine thiocyanate-phenol chloroform method. 37 Northern blot analysis was performed as described previously. 35 Blots containing 10 µg RNA in each sample were hybridized with 32 P-labeled human BACH1, murine p45, murine GATA-1 or chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probes.
RT-PCR
only. These enriched megakaryocytes were cultured in 5% CO 2 at 37 o C for 36 hours. Aliquots of the cells were mounted on slides by cytospin and stained with Giemsa. Acetylcholinesterase activity was detected before counting the megakaryocytes for PPF.
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Culture and purification of primary megakaryocytes
Whole livers were recovered from mouse fetuses between embryonic days 13 and 15, and single cell suspensions were prepared by successive passage through 22-and 25-gauge needles. Fetal liver cells were maintained in DMEM (Nissui, Tokyo) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 units/ml penicillin, 50 ዊg/ml streptomycin, 0.1 mM nonessential amino acids, and 0.1 ዊg/ml recombinant human thrombopoietin (TPO) (Kirin, Gunma) for 5 or 8 days as described previously. 40 To enrich for megakaryocytes, we performed the same purification method used for the PPF assay. The purified cell fraction contained more than 90% large acetylcholinesterase-positive cells
Measurement of megakaryocyte DNA content
DNA ploidy of megakaryocytes in unfractionated bone marrow was determined as previously described. 
Results
Establishment of BACH1 transgenic mouse lines
In order to study the functional contribution of BACH1 to the differentiation and maintenance of erythroid and megakaryocytic lineages in vivo, we generated transgenic lines of mice expressing human BACH1 cDNA under the control of G1-HRD. Three independent transgenic lines of mice were established, and the expression level of the transgene was monitored by Northern blot analysis. Whereas all lines of transgenic mice expressed the transgenic BACH1 mRNA in the spleen, two lines (705 and 706) exhibited higher-level expression than did the remaining line (701, Figure 1A) . We surmise that this may be due to the integrated position effect.
In accordance with our expectations, the expression profile of exogenous BACH1 mRNA was remarkably confined to the spleen ( Figure 1B) . To examine the expression of exogenous BACH1 protein, we carried out immunoblot analysis using antisera against Bach1. 17 We found that BACH1 was abundantly expressed in the spleens of the transgenic mice ( Figure 1C) . In contrast, signals from endogenous Bach1 protein in the wild-type littermate mouse spleen were very faint. Either exogenous or endogenous Bach1 protein was not detectable in the liver. Taken together with the results of Northern blot analysis ( Figure   1A and B), these results showed that exogenous BACH1 was expressed in the transgenic mice at a higher level compared with that of endogenous Bach1. We also examined the expression of GATA-1 and p45 mRNAs in the BACH1 transgenic mouse by Northern blot analysis. The expression levels of GATA-1 and p45 mRNAs in the BACH1 transgenic mice were similar to those of their wild-type littermates, suggesting that overexpression of Bach1 does not affect these factors, which are important in both erythroid and megakaryocytic cells ( Figure 1B) . Northern blot analysis of BACH1, GATA-1, and p45 mRNAs using total RNA derived from various tissues in the transgenic and wild type littermates. Note that BACH1 mRNA was detected only in the spleens of the transgenic mice, while the levels of GATA-1 and p45 expression in the BACH1 transgenic mice were consistent with those of their wild-type littermates. (C) Immunoblotting analysis of BACH1 using tissue extracts from the transgenic mice (706, 706) and their wild type littermates. Extracts were prepared from the spleens, livers and QT6 cells that were transfected with BACH1 expression vector. Twenty µg of tissue extracts and 2 µg of QT6 protein were separated by 7% SDS-PAGE. After electrophoresis, samples were incubated with anti-Bach1 antisera (A1-5). 17 Bound antibody was detected by a peroxidase-conjugated secondary antibody to rabbit immunoglobulin. After stripping off the A1-5 antibody, subsequent immunoblot analysis was performed using an anti-beta-tubulin antibody as a control for the amount of protein loaded in each lane.
Thrombocytopenia in the BACH1 transgenic mice
To investigate whether or not transgenic expression of BACH1 disturbs normal hematopoiesis, we analyzed peripheral blood samples of the transgenic mice. Hematopoietic indices for the transgenic and wild type littermates are shown in Figure 2 . White blood cell counts and red cell indices of the transgenic mice were indistinguishable from those of wild-type mice (Figure 2A-C) , and the morphology of the red cells, granulocytes, and lymphocytes in the peripheral blood was within the normal range in the transgenic mice (data not shown). In contrast, we found significant thrombocytopenia in the two transgenic mouse lines (705 and 706) that expressed BACH1 at a high level, whereas thrombocytopenia was mild in the line 701 mice that expressed a lower level of BACH1 ( Figure 2D) . These results thus demonstrate that the levels of transgene-derived BACH1 mRNA correlate well with the severity of thrombocytopenia. We next examined the change of platelet counts of the transgenic mice in the course of aging, and found there was no significant difference in the platelet counts ( Figure 2E ).
It has been suggested that proplatelet formation (PPF) represents a terminal event in the course of platelet production. 23 Indeed, PPF was decreased in the germ line p45 and in small maf mutant mice that had thrombocytopenia. 21, 29, 30 We therefore examined whether transgenic expression of BACH1 also affects PPF. Our results indicate that PPF was reduced about 30% in the BACH1 transgenic mice compared with their wild-type littermates ( Figure   3 ). We also examined the frequency of megakaryocytic progenitors in the spleen by colony formation analysis, but we could not detect a significant difference in CFU-Meg between the BACH1 transgenic mice and their wild-type littermates (data not shown). These results indicate that transgenic expression of BACH1 suppressed the terminal maturation of megakaryocytes.
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During the maturation process, megakaryocytes acquire a high DNA ploidy by endomitosis. 42 To determine whether the process of megakaryocyte development was affected in BACH1 transgenic mice, we performed DNA ploidy analysis on their bone marrow cells.
The results revealed that CD41 positive megakaryocytes from the transgenic mice showed a significantly lower level of polyploidy than those derived from their wild-type littermates, whereas there were no significant differences in the number of bone marrow megakaryocytes 
Electron microscopic analysis of megakaryocytes from BACH1 transgenic mice
To further characterize the morphological features of megakaryocytes in the transgenic mice, we performed electron microscopic analysis. In contrast to megakaryocytes in wild-type mice, which exhibited well-formed platelet territories with the development of demarcation membranes, megakaryocytes from BACH1 transgenic mice showed serious impairment of the platelet field formation, and lacked demarcation membranes. Megakaryocytes from the transgenic mice had a lower degree of nuclear complexity and different heterochromatin contents, compared to those from the wild-type littermates. Moreover, this ultrastructural analysis of megakaryocytes from the transgenic mice revealed the vacuolation of mitochondria and a deficit in the number of -granules ( Figure 5B) . Emperioporesis was also detected in many megakaryocytes from the transgenic mice ( Figure 5B) . Taken together, these results further support our contention that thrombocytopenia is caused primarily by a failure of megakaryocyte maturation and platelet development. 
Histological analysis of hematopoietic tissues in BACH1 transgenic mice
We next carried out histological analyses of hematopoietic tissues from the BACH1 transgenic mice. An important observation was that a reduction of the femoral cavity was found upon microscopic examination, and this was perhaps due to increased osteogenesis in the transgenic mice ( Figure 6B ). In addition, consistent with the electron microscopic analysis (see above), we observed emperioporesis of granulocytes in megakaryocytes, specifically in the transgenic mice ( Figure 6D ).
It should also be noted that reticulin fibrosis in the bone marrow of the transgenic mice was markedly identifiable by silver impregnation (Figure 6F 
Expression of p45 target genes in megakaryocytes of BACH1 transgenic mice
Since the phenotype of the BACH1 transgenic mice resembled that of the p45-deficient mice, it was thought that transgenic expression of BACH1 might repress the transcriptional activation mediated by p45. Therefore, to address this point, we examined the expression of the p45 NF-E2 target genes in the primary megakaryocytes from fetal liver cells of the BACH1 transgenic mice. RT-PCR analyses showed that expression of the hematopoietic-specific 1-tubulin, TXAS, and of the 3 -hydroxy-steroid dehydrogenase (3 -HSD) genes was significantly downregulated in the megakaryocytes from BACH1 transgenic mice (Figure 7) . However, one of the G tubulin isoforms, 5-tubulin, which was reported not to be affected in p45-deficient megakaryocytes, 25 was expressed equally in BACH1-transgenic and control megakaryocytes. The expression of GATA-1 and p45 was marginally lower in BACH1 transgenic megakaryocytes than in control mice. These results thus support our contention that the expression of p45 target genes is specifically downregulated in the BACH1 transgenic megakaryocytes. 
In vivo binding of BACH1 to the TXAS gene enhancer.
The TXAS gene is a well-known MARE-dependent gene containing functional MAREs in its promoter and in the second intron ( Figure 8B) . Therefore, to ask whether BACH1 actually binds to MARE in the megakaryocytic genes, we performed chromatin immunoprecipitation (ChIP) analysis with a BACH1-specific antibody. Since it is technically not feasible to use megakaryocytes from mouse bone marrow for this assay, we looked for a cultured megakaryocytic cell line. A megakaryocytic subline of UT-7 cells, UT-7/TPO, 34 which has mature megakaryocytic features, seemed to be suitable for this analysis, along with the erythroid subline UT-7/EPO. 33 We first confirmed that both BACH1 and TXAS genes are expressed in the UT-7/TPO subline ( Figure 8A) . A ChIP assay with UT-7/TPO cells demonstrated that BACH1 bound to the promoter and enhancer regions in vivo. In contrast, BACH1 was not enriched at the only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From promoter region in UT-7/EPO cells, whereas it did bind to the enhancer (Figure 8C) . To determine the specificity of these binding interactions, we looked for the exon 13-region in chromatin immunoprecipitates, which is approximately 190-kb downstream from the promoter. No significant enrichment of the exon 13-region was detected by ChIP analysis, confirming the specificity of this assay.
Previous reports showed that Bach1 can repress reporter gene expression, when the reporter gene contains MARE in the promoter proximal region in transfect. We asked whether expression of the Bach1 protein repressed the reporter gene through the TXAS promoter. For sthis purpose, we prepared a reporter plasmid containing the TXAS promoter fused to the luciferase gene, and transfected the reporter with the expression vectors for BACH1 or Bach1-MafK fusion protein (B1K) into QT6 quail fibroblasts 35 and into the megakaryoblast cell line CMK11-5. As expected, co-transfection with BACH1 or B1K expression plasmids repressed the reporter gene activity driven by the TXAS promoter in a dose dependent manner (Figure 9) . The transcriptional repression was more significant for B1K transfects than for the BACH1 transfects. Taken together, these results suggest that BACH1 binds to MARE in its regulatory region, and acts as a repressor in megakaryocytes. (A) RT-PCR analysis of TXAS, BACH1, and p45 mRNA in UT-7/EPO and UT-7/TPO cells. The TXAS gene was expressed in UT-7/TPO, whereas the TXAS gene was detected only marginally in UT-7/EPO. Input RNA levels were normalized using G3PDH transcripts as controls. To ensure linearity of the PCR reactions, 10-fold serial dilutions of template cDNA were used. PCR products were electrophoresed using Bioanalyzer 2100 and DNA1000 LabChip kits. (B) Schematic representation of the human TXAS gene. The regions amplified by the ChIP assay were shown to be nfe2-1, nfe2-3, and exon 13. The nfe2-1 and nfe2-3 sites contain the MARE, which has been implicated in TXAS gene expression. (C) ChIP analysis using an anti-Bach antibody (A1-5) in UT-7/EPO and UT-7/TPO. Gel images show PCR only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From products corresponding to nfe2-1, nfe2-3 and exon 13, obtained using input (lanes 1 and 4) and precipitated chromatin as templates (lanes 2, 3, 5 and 6). The exon 13 template DNA was used as a control. Fragments containing MARE located in the second intron (nfe2-1) or in their proximal promoter (nfe2-3) were precipitated by an anti-Bach1 antibody in UT-7/EPO (lane 3) or in UT-7/TPO (lane 6). Normal mouse IgG was used as a control (lanes 2 and 5). These results represent four independent experiments.
Figure 9. Regulation of TXAS gene promoter activity by BACH1.
A luciferase reporter construct containing a 535-bp fragment that included the transcription initiation site for the TXAS gene was transiently co-transfected with BACH1 or the Bach1-MafK chimeric protein expression plasmid (B1K) into QT6 fibroblasts by Lipofectamin (A), as well as the megakaryoblast cell line CMK11-5, by Nucleofector (B). The respective relative luciferase activity (meanዊSD of four independent experiments in QT-6, and three in CMK11-5) is shown. Each activity was standardized by reference to the -galactosidase activity from the co-transfected expression plasmid, which was driven by the elongation factor 1 promoter.
Discussion
We found in this study that transgenic expression of BACH1 in megakaryocytes in vivo results in thrombocytopenia. This is most likely due to maturation arrest of megakaryocytic cells and resulting dysfunctions in platelet formation. Transgenic BACH1 gives rise to these deleterious effects through heterodimerizing with one of the small Maf proteins. This heterodimer binds to MARE, and it has been well demonstrated that the small Maf-p45 heterodimer binds to MARE and activates gene expression. 6, 7 Thus, this study further supports our contention that cis-acting MARE acts as a critical regulatory element for megakaryocytic genes during megakaryocyte differentiation. 29, 30, 39 Importantly, the phenotype of BACH1 transgenic mice resembles that of the p45-null mice; p45-null mice showed profound thrombocytopenia associated with increased production of abnormal megakaryocytes. 21, 22 Megakaryocytes lacking p45 show polyploidy, which is characterized by a large cytoplasm containing abundant but disorganized demarcation membrane, and a reduced number of platelet-specific granules. Furthermore, megakaryocytes from p45 knockout mice and BACH1 transgenic mice both showed emperioporesis. These similarities in the megakaryocytic phenotype suggest the presence of common or overlapping mechanisms underlying the impaired megakaryopoiesis observed in these mutant mice.
However, in contrast to p45-null mice, the number of megakaryocytes was not increased in BACH1 transgenic mice, and BACH1-overexpressing megakaryocytes did not complete endomitosis. These differences may indicate the disparity of the target genes of these transcription factors.
Transgenic mouse lines expressing small Maf proteins under the control of G1-HRD have been reported, and these lines of mice showed a reduction of PPF activity. 39 Since small
Maf proteins form unproductive homodimers by themselves, we surmise that transgenic small Maf proteins block small Maf-p45 heterodimer formation or binding. Similarly, it is plausible only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From that BACH1 blocks the small Maf-p45 heterodimer function when BACH1 is overexpressed in a megakaryocytic lineage. Consistent with this notion, the expression of three p45 target genes was significantly repressed in the BACH1-expressing megakaryocytes. Although the physiological function of BACH1 in megakaryocytes remains to be clarified, our results suggest that the dynamic exchange of BACH1-p45 heterodimer formation at MARE may also occur during differentiation of hematopoietic cells toward the megakaryocytic lineage. In this regard, it should be noted that a Bach1 gene-targeting experiment was recently carried out. 43 The Bach1-null mutants are fertile and within a normal size range. Platelet counts in their peripheral blood are also within the normal range (Igarashi K, unpublished results). To further clarify the roles of Bach1 in mice, therefore, it will be necessary to analyze thrombopoiesis in knockout mutant mice in which thrombocytopenia has been induced by irradiation or chemotherapy. We are now planning such a study.
In contrast to p45-null mutant mice, the BACH1 transgenic mice did not develop anemia.
Recently, we demonstrated that heme inhibits the DNA binding activity of the Bach1-MafK heterodimer by directly interacting with Bach1 through a di-peptide motif of cysteine and proline. 44 As erythroid cells synthesize large amounts of heme for hemoglobin, one plausible explanation for the absence of significant changes in the erythroid phenotype of the BACH1 transgenic mice is that there may be interference with Bach1 binding to its target sequence by heme that accumulates inside the erythroid cells.
One of the most striking phenotypes in the BACH1 transgenic mice is the development of myelofibrosis. A number of reports suggest that alterations in megakaryopoiesis, with accumulation of abnormal megakaryocytes may be essential for the development of myelofibrosis. GATA-1-low mice, which are a genetically modified mouse line lacking upstream regions of the GATA-1 gene, show profound thrombocytopenia with dysregulated megakaryocyte proliferation and impaired cytoplasmic maturation of megakaryocytes. [45] [46] [47] only.
The spleens of GATA-1-low mice showed an increase in the number of megakaryocytes as compared to littermate controls, and these megakaryocytes were smaller than wild-type megakaryocytes. They contained scant cytoplasm, condensed nuclei, and a disorganized demarcation membrane.
Recently, GATA-1-low mice were reported to develop a disease resembling human idiopathic myelofibrosis (IM). 48 IM is a myeloproliferative disorder of clonal origin that is characterized by fibrotic degeneration of the bone marrow and extramedullary hematopoiesis in the spleen and liver. 49 IM cases also show the presence of tear-drop poikilocytes, collagen fibers in the bone marrow and spleen, and hematopoietic foci in the liver. However, in the GATA-1-low mice, early IM traits such as the presence of reticulin fibers in bone marrow and spleen were detected only after 10 months of age, and the disease progressed slowly to a frank IM after 15 months. In contrast, in the BACH1 transgenic mice the reticulin fibrosis could be detected as early as five weeks of age, but we did not observe progression to IM in these transgenic mice (data not shown). Although the numbers of megakaryocytes did not increase, megakaryocytes in the BACH1 transgenic mice showed abnormal morphology and function, suggesting that some alteration in regulatory pathways might occur in the BACH1-expressing megakaryocytes, and this may lead in turn to myelofibrosis.
In the GATA-1-low mice, induced expression of several growth factors is implicated in the development of myelofibrosis. Growth factors, such as osteocalcin, transforming growth factor-, platelet-derived growth factor, and endothelial growth factor were increased in the bone marrow of GATA-1-low mice, but the expression of these cytokines within the GATA-1 deficient megakaryocytes was not affected. 48 Further analysis of cytokine production in the BACH1 transgenic mice may help to reveal the mechanism of fibrosis.
The human BACH1 gene is localized to chromosome 21q22.1 50, 51 within the Down's syndrome-associated gene region. have an approximately 20-fold higher incidence of leukemia than unaffected children. 53 The majority of leukemia cases associated with Down's syndrome are acute megakaryocytic leukemia (AMKL). 54 Recently, we and others have demonstrated that mutagenesis of the GATA-1 gene is a very early event in the development of Down's syndrome-related AMKL (DS-AMKL), during the process of multi-step leukemogenesis. Acquired mutations of the GATA-1 gene have been detected in almost all cases in DS-AMKL and transient myeloproliferative disorder (TMD), "a preleukemia" that may be present in as many as 10% of newborn infants with Down's syndrome. [55] [56] [57] [58] [59] [60] We envisage that mutations in GATA-1 may not be the first event, because the GATA-1 gene is located on the X chromosome.
To further understand the mechanisms of a lineage-specific malignant conversion, it is very important to identify the gene or genes in chromosome 21 that cooperate with the GATA-1 mutant during leukemogenesis. Although the BACH1 transgenic mice did not develop leukemia per se, the present data show that terminal differentiation of the megakaryocytes, as well as platelet production, were markedly impaired by the overexpression of BACH1. These results support our contention that BACH1 is one of the candidates for genes that cooperate with the mutated GATA-1 at a very early stage of leukemogenesis in Down syndrome. In this regard, experiments are now underway to characterize a cross between the BACH1 transgenic mice described here and GATA-1 gene knockdown mice rescued with an N-terminal domain-defective mutant of GATA-1. 
